Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

Journal of Hematology & Oncology

Weidong Han¹  Yufang Shi²  Changshun Shao²  Xiaolei Li² 

[1] Department of Molecular Biology, Immunology and Bio-therapeutic, Institute of Basic Medicine, Chinese PLA General Hospital;The First Affiliated Hospital of Soochow University and Jiangsu Engineering Research Center for Tumor Immunotherapy, Institutes for Translational Medicine and Suzhou Key Laboratory of Tumor Microenvironment and Pathology, Soochow University;

关键词: Cancer immunotherapy;    Immune checkpoint blockade;    Tumor microenvironment;    Resistance mechanism;    Combination immunotherapy;   

DOI  :  10.1186/s13045-018-0578-4

来源: DOAJ

【 摘 要 】

Abstract The advent of immunotherapy, especially checkpoint inhibitor-based immunotherapy, has provided novel and powerful weapons against cancer. Because only a subset of cancer patients exhibit durable responses, further exploration of the mechanisms underlying the resistance to immunotherapy in the bulk of cancer patients is merited. Such efforts may help to identify which patients could benefit from immune checkpoint blockade. Given the existence of a great number of pathways by which cancer can escape immune surveillance, and the complexity of tumor-immune system interaction, development of various combination therapies, including those that combine with conventional therapies, would be necessary. In this review, we summarize the current understanding of the mechanisms by which resistance to checkpoint blockade immunotherapy occurs, and outline how actionable combination strategies may be derived to improve clinical outcomes for patients.

【 授权许可】

Unknown